Skip to content
USPeptideRxLearnApply for an account

Glossary

503B outsourcing facility: registration is elected, and it does not travel

USPeptideRx EditorialLast reviewed:

A 503B outsourcing facility is a facility that has elected to register with the FDA under 21 U.S.C. § 353b. Two features follow, and they are the whole reason the category exists: it is subject to current good manufacturing practice and to FDA inspection on a risk-based schedule, and it may supply compounded drugs against an order from a health care provider that names no individual patient. That second feature is what makes it the federal route for office stock. What it is not is permission to ship anywhere — section 503b exempts a facility from certain federal requirements and preempts no state licensing scheme, so the destination state’s own credential is still required.

Registration is elected, not granted

The category is unusual in that a facility opts into it. North Carolina’s statute recites the federal mechanism in a single clause, and the verb is the informative part:

N.C. G.S. § 106-140.1(j)(1a)
a manufacturer at a single geographic location or address that is engaged in the compounding of sterile drugs, has elected to register as an outsourcing facility with the Food and Drug Administration, and complies with the requirements as provided in 21 U.S.C. § 353b

"Has elected to register" is not "has been approved." No agency issues this status on the merits of an application, and registering does not make a facility’s products approved — compounded drugs are not FDA-approved, whichever section they were made under.

What it may supply, and what it pays for that

FDA states the trade in one sentence, contrasting these facilities with compounders operating under the other section.

FDA — Human drug compounding: the laws (quoted from mid-sentence; the omitted opening draws the contrast with compounders under the other section)
outsourcing facilities are subject to CGMP requirements, and they may distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock).

That is the federal answer to how a practice gets a cabinet stocked, and it is why so many state rules name the section by number when they close the other door. Illinois writes the route into its own compounding rule.

68 Ill. Adm. Code 1330.640(c)
Sterile compounding for office use is prohibited unless the pharmacy is in full compliance with 21 USC 353b, including becoming registered as an outsourcing facility and licensed as a wholesale drug distributor pursuant to the Wholesale Drug Distribution Licensing Act [225 ILCS 120].

The price of the arrangement is the manufacturing regime. A facility here is subject to cGMP and to FDA inspection on a risk-based schedule. Compounding under section 503A is exempt from cGMP and pays instead with the patient-specific prescription condition — the comparison in full is 503A vs 503B.

Registration does not travel

This is the error with the most practical consequence. Section 353b is an exemption from specified federal requirements. It preempts no state licensing scheme, and it regulates the facility rather than the facility’s customer, so the receiving side stays a question of state law.

A facility that satisfies the federal section in full and holds no credential where you practise is not compliant — it is federally clean and exposed in your state. The credential it needs there is defined at non-resident pharmacy licence, and in several states it is issued by an agency other than the board of pharmacy. Whether your own practice needs a permit to take delivery is a third question again: see terminal distributor of dangerous drugs and how to place an office-use order.

Unlike the other pathway, this one has a public federal register: FDA lists every registered facility with its last inspection date and whether an action followed. Using it is step one of how to vet a compounding pharmacy.

Not a manufacturer, though several states license it as one

The term a state puts on the credential is its own, and it is often "manufacturer" — Arizona permits a facility registered under section 503B as a drug manufacturer, and North Carolina's statutory definition opens by calling one. That is the state's licensing vocabulary being coarser than the federal category, not a statement that the two are the same thing. Which obligations actually differ, and which are shared, is set out at a 503B outsourcing facility and a drug manufacturer compared.

What this page does not establish

  • No verbatim text of 21 U.S.C. § 353b was retrieved for this page. The section is cited and linked; the descriptions of what it requires come from FDA’s own account of the law and from state statutes that recite it, each quoted and attributed below.
  • The statement that the destination state’s credential is also required reflects the states with a completed primary-source briefing on this site. In one of them — Georgia — the carve-out for these facilities is established but no state credential requirement was verified either way, and the states not reviewed are unknown.
  • Nothing here describes the registration status, inspection history or compliance of any particular facility, including any we work with. FDA’s own register is linked so a reader can check a named facility themselves.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.

  1. [1]21 U.S.C. § 353b — Outsourcing facilities (Cornell LII)
  2. [2]FDA — Human drug compounding: the laws
  3. [3]FDA — Registered outsourcing facilities (the public register, with inspection outcomes)
  4. [4]N.C. G.S. § 106-140.1 — registration, including the definition reciting the federal election
  5. [5]68 Ill. Adm. Code 1330.640 — Pharmaceutical Compounding Standards